3
Views
0
CrossRef citations to date
0
Altmetric
Research

Patent Evaluation: Biologicals & Immunologicals: Viral proteins for the suppression of neu-mediated transformation

Pages 71-72 | Published online: 29 Feb 2008

References

  • EVAN GI, WYLLIE AFL GILBERT CS, LITTLEWOOD TD, LAND H, BROOKS M, WATERS CM, PENN LZ, HANCOCK DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell (1992) 69:119–128.
  • TEODORO JG, SHORE GC, BRANTON PE: Adenovirus Ela proteins induce apoptosis by both p53-dependent and p53-independent mechanisms. Oncogene (1995) 11:467–474.
  • RAO L, DEBBAS M, SABBATTNI P, HOCKENBERY D, KORS-MEYER S, WHITE E: The adenovirus Ela proteins induce apoptosis, which is inhibited by the Elb 19-1(Da and bc1-2 proteins. Proc. Natl. Acad. Sci. USA (1992) 89:7742–7746.
  • HARRIS RA, HILES ID, PAGE MJ, O'HARE MJ: The induction of apoptosis in human mammary luminal epithelial-cells by expression of activated c-neu and its abrogation by glucocorticoids. Br. J. Cancer (1995) 72:386–392.
  • BETT AJ, HADDARA W, PREVEC L, GRAHAM FL: An effi-cient and flexible system for construction of ade-novirus vectors with insertions or deletions in early region-I and region-3. Proc. Natl. Acad. Sci. USA (1994) 91:8802–8806.
  • LEARY JA, EDWARDS BG, HOUGHTON CRS, KEFFORD RF, FRIEDLANDER ML: Amplification of her-2/neu oncogene in human ovarian-cancer. Int. J. Gynecol. Cancer (1992) 2:291–294.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.